Results 21 to 30 of about 179,934 (163)

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

OncoImmunology, 2021
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors.
Hua You, Zijun Y. Xu-Monette, Li Wei, Harry Nunns, Máté L. Nagy, Govind Bhagat, Xiaosheng Fang, Feng Zhu, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han Van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Qingyan Au, Bing Xu, Maher Albitar, Ken H. Young   +28 more
doaj   +1 more source

Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants [PDF]

, 2021
Germline pathogenic variants in TP53 are associated with Li-Fraumeni syndrome, a cancer predisposition disorder inherited in an autosomal dominant pattern associated with a high risk of malignancy, including early-onset breast cancers, sarcomas ...
Slavin, Thomas P, Zhang, Liying, Fortuno, Cristina, Seifert, Bryce A, Plon, Sharon E, Spurdle, Amanda B, Frone, Megan N, Andrade, Kelvin C, Olivier, Magali, Evans, D Gareth, Foreman, Ann KM, Pesaran, Tina, Panel, the ClinGen TP53 Variant Curation Expert, Savage, Sharon A, McGoldrick, Kelly, Mai, Phuong L, Mester, Jessica, Attardi, Laura D, James, Paul A, Crowley, Stephanie, Feng, Bing‐Jian, Witkowski, Leora, Lee, Kristy, Huether, Robert   +23 more
core   +1 more source

Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. [PDF]

, 2012
Non-melanoma skin cancers are one of the most common human malignancies accounting for 2-3% of tumors in the US and represent a significant health burden.
Kiviat Nancy B., Qinghua Feng, Nancy B Kiviat, Loeb Keith R., Stephen E. Hawes (168704), Mingjun Jiang, Stern Joshua E., Nancy B. Kiviat (168749), Joshua E. Stern (168716), Feng Qinghua, Keith R Loeb, Zsolt B Argenyi, Maryam M. Asgari (168700), Mingjun Jiang (168725), Asgari Maryam M., Stephen E Hawes, Jiang Mingjun, Maryam M Asgari, Hawes Stephen E., Argenyi Zsolt B., de Villiers Ethel-Michele, Ethel-Michele de Villiers (8400), Ethel-Michele de Villiers, Qinghua Feng (168708), Keith R. Loeb (168697), Joshua E Stern, Zsolt B. Argenyi (168735)   +26 more
core   +1 more source

The TP53 fertility network [PDF]

, 2012
The TP53 gene, first described in 1979, was identified as a tumor suppressor gene in 1989, when it became clear that its product, the p53 nuclear phosphoprotein, was frequently inactivated in many different forms of cancers.
Paixão Côrtes, Vanessa Rodrigues, Prolla, Patrícia Ashton, Bortolini, Maria Cátira, Paskulin, Diego D'Ávila, Hainaut, Pierre   +4 more
core   +2 more sources

A TP53-mutáció-analízis jelentősége krónikus lymphocytás leukaemiában | TP53 mutation analysis in chronic lymphocytic leukaemia [PDF]

, 2017
Absztrakt: Bevezetés: Az elmúlt években jelentős előrelépések történtek a krónikus lymphocytás leukaemia kezelésében, ugyanis az új innovatív gyógyszerek a TP53-defektust hordozó csoportban is ...
Gurbity Pálfi, Tímea, Péter Farkas, Marosvári, Dóra, Mátrai Zoltán, Kajtár, Béla, Matolcsy András, Marosvári Dóra, Fesus V, Kajtár Béla, Plander M, Márk Plander, Dóra Marosvári, Mátrai, Zoltán, Fésűs Viktória, Matolcsy, András, Péter Attila Király, Király, Péter Attila, Farkas, Péter, Bödör, Csaba, Demeter Judit, András Matolcsy, Egyed Miklós, Bödör Csaba, Fésüs, Viktória, Judit Demeter, Viktória Fésüs, Demeter, Judit, Egyed, Miklós, Zoltán Mátrai, Plander, Márk, Farkas Péter, Csaba Bödör, Király Péter Attila, Tímea Gurbity Pálfi, Gurbity Palfi T, Miklós Egyed, Gurbity Pálfi Timea, Béla Kajtár   +37 more
core   +1 more source

Acute Mast Cell Leukemia Preceded by Malignant Mediastinal Germ Cell Tumor: A Case Report and Literature Review

Cancer Management and Research, 2022
Huafang Wang,1 Yuan Chen,2 Huijun Lin,3 Wanmao Ni,4 Qiaolei Zhang,5 Jianping Lan,1 Lai Jin1 1Cancer Center, Department of Hematology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang ...
Wang H, Chen Y, Lin H, Ni W, Zhang Q, Lan J, Jin L   +6 more
doaj  

Molecular and clinical aspects of HNSCC in the Republic of Moldova

Romanian Journal of Laboratory Medicine, 2023
Introduction: Complex molecular characterization and integrated approaches in the basic research of HNSCC provide new insights into the understanding and treatment of these tumors.
Stratan Valentina, Țuțuianu Valeri, Sîtnic Victor, Popa Cristina, Balan Veronica, Clipca Adrian, Sclifos Ina, Monastirscaia Anastasia, Trohin Victoria, Sprincean Mariana   +9 more
doaj   +1 more source

The relationship between TP53 and clinicopathological characteristics and their impact on the survival prognosis of patients with stage Ⅱ/Ⅲ colorectal cancer

结直肠肛门外科, 2023
[Objectives] To investigate TP53 and clinicopathological characteristics on the survival prognosis of patients with stage Ⅱ/Ⅲ colorectal cancer. [Methods] The clinical data of 57 patients with stage Ⅱ/Ⅲ colorectal cancer who were admitted to Wenzhou ...
Huang Lifeng, Huang Jian, Fan Yufang, Chen Yuemiao, Jiang Wei, Bao Yinghong, Cai Xiaoping   +6 more
doaj   +1 more source

Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review

Chinese Journal of Lung Cancer, 2023
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer.
Donglai LV, Chunwei XU, Chong WANG, Qiuju SANG   +3 more
doaj   +1 more source

TP53-TA

, 2017
TP53-TA ...
KHALID MAHMOOD (1120670)
core   +1 more source